DIJG
$MDNAF Exceptional result. I'm pleased the market isn't punishing the stock, even if the share price hasn't yet responded the way many expected. Price action can lag reality, but eventually the value of strong clinical data tends to be recognized.
The key risk was always whether the drug could generate meaningful efficacy. That question has now been answered. From here, the focus shifts to regulatory execution: defining the registrational pathway, meeting with the FDA, and aligning on Project Optimus requirements. A partnership deal will likely hinge on those discussions, but with data of this quality, MDNA11 has become very difficult for the industry to ignore.
14
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault16.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault23.jpg)